Gainers
-
Aimmune Therapeutics Inc (NASDAQ: AIMT) rose 46.2
percent to $37.51 in pre-market trading in response to failed DBVT peanut allergy trial.
-
Evoke Pharma Inc (NASDAQ: EVOK) rose 22.4 percent
to $4.21 after the company disclosed 'positive' topline results from comparative exposure pharmacokinetic study for Gimoti.
-
Agenus Inc (NASDAQ: AGEN) rose 17.6 percent to
$5.09 in pre-market trading as the company disclosed that GSK's shingle vaccine received FDA approval.
-
BroadSoft Inc (NASDAQ: BSFT) rose 16.9 percent to
$63.00 in pre-market trading after Reuters reported that Cisco is nearing a deal to acquire BroadSoft.
-
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) shares
rose 12.5 percent to $2.25 in pre-market trading after the company disclosed that DSUVIA clinical trial results selected as a
top abstract for oral presentation at ASA's Annual Meeting.
-
Xunlei Ltd (NASDAQ: XNET) shares rose 8.8 percent
to $7.16 in pre-market trading after surging 25.33 percent on Friday.
-
Deltic Timber Corp (NYSE: DEL) shares rose 7.1
percent to $95.39 in pre-market trading after Potlach announced plans to merge with Deltic.
-
Renren Inc (NYSE: RENN) rose 6.4 percent to $10.18
in pre-market trading after gaining 2.68 percent on Friday.
-
Hoegh LNG Partners LP (NYSE: HMLP) rose 5.9 percent
to $20.60 in the pre-market trading session after gaining 0.52 percent on Friday.
-
Pluristem Therapeutics Inc. (NASDAQ: PSTI) shares
rose 5.7 percent to $1.87 in pre-market trading after the company announced a European Patent for RLX-R18.
-
Scorpio Bulkers Inc (NASDAQ: SALT) rose 5.5
percent to $8.65 in pre-market trading. Scorpio Bulkers posted a Q3 loss of $0.15 per share on revenue of $38.61 million.
-
NovaGold Resources Inc. (USA) (NYSE: NG) rose 4.6
percent to $4.31 in pre-market trading after dropping 0.48 percent on Friday.
-
VF Corp (NYSE: VFC) shares rose 4 percent to $69.00
in the pre-market trading session after the company reported upbeat earnings for its third quarter and raised its FY2017
guidance.
-
Caesars Entertainment Corp (NASDAQ: CZR) rose 3.7
percent to $12.65 in pre-market trading after gaining 1.24 percent on Friday.
-
Halliburton Company (NYSE: HAL) shares rose 3.2
percent to $44.69 in pre-market trading after the company reported stronger-than-expected profit for its third quarter on
Monday.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
Losers
-
DBV Technologies SA - ADR (NASDAQ: DBVT) fell
44.6 percent to $26.61 in pre-market trading after the company disclosed that its peanut allergy trial failed to meet primary
endpoint.
-
8Point3 Energy Partners LP (NASDAQ: CAFD) fell
11.7 percent to $13.70 in pre-market trading after rising 0.39 percent on Friday.
-
Myomo Inc (NYSE: MYO) shares fell 9.3 percent to
$2.95 in pre-market trading after dropping 7.98 percent on Friday.
-
Sphere 3D Corp. (NASDAQ: ANY) fell 8.5 percent to
$2.15 in pre-market trading after declining 0.84 percent on Friday.
-
Global Blood Therapeutics Inc (NASDAQ: GBT) shares
fell 7.8 percent to $30.00 in pre-market trading after the company reported discontinuation of idiopathic pulmonary fibrosis
program.
-
Westlake Chemical Corporation (NYSE: WLK) shares
fell 5 percent to $79.68 in pre-market trading. Westlake Chemical is expected to release its Q3 earnings on Tuesday, November
7, 2017.
- Mercadolibre Inc NASDAQ: MELI) fell 4.6 percent to $224.85 in pre-market trading. KeyBanc downgraded MercadoLibre from
Overweight to Sector Weight.
-
IPG Photonics Corporation (NASDAQ: IPGP) shares
fell 4.2 percent to $194.17 in pre-market trading after gaining 0.85 percent on Friday.
-
Viking Therapeutics Inc (NASDAQ: VKTX) shares
fell 3.7 percent to $2.89 in pre-market trading. Viking Therapeutics presented results from proof-of-concept study of VK0214 in
in vivo model of X-linked adrenoleukodystrophy.
-
Harsco Corporation (NYSE: HSC) fell 3.3 percent to
$20.80 in the pre-market trading session. Harsco is projected to release Q3 results on November 8, 2017.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.